Setmelanotide shows long-term benefits in acquired hypothalamic obesity

CHICAGO — In patients with acquired hypothalamic obesity, treatment with setmelanotide for 2.5 years was associated with sustained reductions in age-related weight metrics, according to findings from a long-term extension study. The study, presented at ENDO 2026, included 14 participants (12 younger than 18 years) who completed a 16-week phase 2 trial of setmelanotide (Imcivree, Rhythm